Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

AQR Capital Holdings

2,714.10
+0.68120.03%
Number of Gainers:57
Number of Losers:39
Number of Flat:2
PE:- -
High:2,718.55
Open:2,713.61
Low:2,706.88
Close:2,713.41
Volume:301.26M
Turnover:69.08B
Market Cap:49.64T
Float Cap:46.18T

Loading ...

OverviewNews

Top Midday Stories: Nvidia Adds Local AI Options; Nike's Weak Fiscal 2027 Outlook; Paramount Skydance to Change Name

MT Newswires Live
·
Oct 03

Nike Stock Considered at Risk of Further Declines

Dow Jones
·
Oct 03

United Parcel Service Likely to Deliver In-Line Results, UBS Says

MT Newswires Live
·
Oct 02

Google Cloud: Announces General Availability of Spanner Queues for Transactional Messaging in AI Agent Workloads - Blog

THOMSON REUTERS
·
Oct 02

Nvidia Stock (NVDA) Hits All-Time High Days After Announcing Record Buyback

TIPRANKS
·
Oct 02

Nike's Right-Sizing Efforts are Dragging

Dow Jones
·
Oct 02

Amazon and Microsoft Cloud Businesses Could Face Tougher EU Rules as Soon as November

TIPRANKS
·
Oct 02

Update: BofA Securities Adjusts Nike Price Target to $24 From $30, Maintains Underperform Rating

MT Newswires Live
·
Oct 02

NVIDIA Launches 64GB DGX Spark With Halved Memory Starting at $4,999, While 128GB Version Jumps to $6,950

Deep News
·
Oct 02

Expeditors International of Washington Seen Benefiting From Stronger Ocean Rates, Airfreight Growth, UBS Says

MT Newswires Live
·
Oct 02

Can Google's New Flagship Model Finally Match OpenAI and Anthropic at the Frontier?

Deep News
·
Oct 02

Biogen Says Litifilimab Posts Sustained Skin Clearance in 52-Week Phase 2 Cutaneous Lupus Study

Reuters
·
Oct 02

Biogen - 28.8% of Participants Achieve 70% or Greater Reduction in Clasi a at Week 52

THOMSON REUTERS
·
Oct 02

Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 Amethyst Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus~

THOMSON REUTERS
·
Oct 02

Biogen - Serious Adverse Events Occurred in 3.4% of Participants During 52-Week Treatment Period

THOMSON REUTERS
·
Oct 02

Biogen - 33.7% of Crossover Participants Report Clear or Almost Clear Skin at Week 52

THOMSON REUTERS
·
Oct 02

hy Nvidia and Broadcom Stocks Are Climbing Today — and How Far Wall Street Sees Them Going

TIPRANKS
·
Oct 02

Nike's Downward EPS Revisions Could Continue, UBS Says

MT Newswires Live
·
Oct 02

Verizon is Maintained at Sector Outperform by Scotiabank

Dow Jones
·
Oct 02

Pfizer Says Phase 3 Trials Show Litfulo Improves Repigmentation in Nonsegmental Vitiligo Patients at Week 52

Reuters
·
Oct 02
More